peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Coffee and notepad

Press releases

2023

26 Oct 2023, 07:00 | Regulatory
•    Encouraging high-level results for first-in-human trial of HNSA-5487
•    Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences
•    Dr. Hitto Kaufmann appointed new CSO
11 Oct 2023, 18:35 | Regulatory
Biologic License Application submission expected for 2025 
9 Oct 2023, 17:35
HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR development program
20 Jul 2023, 07:00 | Regulatory

· Solid product sales in Q2 2023
· Collaboration announced in gene therapy with Genethon in Crigler-Najjar syndrome
· New Eurotransplant desensitization program implemented in June
· First patient treated in new investigator-initiated Phase 2 study in ANCA-associated vasculitis
Load more
Coffee and notepad

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.